These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24860972)

  • 1. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
    Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
    Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
    Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
    Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.
    Zhao B; Mei Y; Cao L; Zhang J; Sumagin R; Yang J; Gao J; Schipma MJ; Wang Y; Thorsheim C; Zhao L; Stalker T; Stein B; Wen QJ; Crispino JD; Abrams CS; Ji P
    J Clin Invest; 2018 Jan; 128(1):125-140. PubMed ID: 29202466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
    Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
    Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
    Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
    J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Wang J; Ishii T; Zhang W; Sozer S; Dai Y; Mascarenhas J; Najfeld V; Zhao ZJ; Hoffman R; Wisch N; Xu M
    Leukemia; 2009 Sep; 23(9):1577-86. PubMed ID: 19387466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.
    Mazzeo C; Quan M; Wong H; Castiglione M; Kaushansky K; Zhan H
    Blood Cells Mol Dis; 2021 Sep; 90():102585. PubMed ID: 34139651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
    Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
    Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
    Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
    Li Z; Xu M; Xing S; Ho WT; Ishii T; Li Q; Fu X; Zhao ZJ
    J Biol Chem; 2007 Feb; 282(6):3428-32. PubMed ID: 17178722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
    Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
    Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional interdependence of hematopoietic stem cells and their niche in oncogene promotion of myeloproliferative neoplasms: the 159th biomedical version of "it takes two to tango".
    Zhan H; Kaushansky K
    Exp Hematol; 2019 Feb; 70():24-30. PubMed ID: 30593829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.